## SAH

Cat. No.:	HY-19528
CAS No.:	979-92-0
Molecular Formula:	C <sub>14</sub> H <sub>20</sub> N <sub>6</sub> O <sub>5</sub> S
Molecular Weight:	384.41
Target:	Endogenous Metabolite
Pathway:	Metabolic Enzyme/Protease
Storage:	-20°C, protect from light * In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

### SOLVENT & SOLUBILITY

®

MedChemExpress

In Vitro	DMSO : 62.5 mg/mL (162.59 mM; ultrasonic and warming and heat to 60°C)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	2.6014 mL	13.0069 mL	26.0139 mL		
		5 mM	0.5203 mL	2.6014 mL	5.2028 mL		
		10 mM	0.2601 mL	1.3007 mL	2.6014 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.41 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.41 mM); Clear solution						
	3. Add each solvent o Solubility: ≥ 2.08 m	ne by one: 10% DMSO >> 90% co g/mL (5.41 mM); Clear solution	orn oil				

BIOLOGICAL ACTIVIT				
Description	SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine <sup>[1]</sup> . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC <sub>50</sub> of 0.9 μM <sup>[2]</sup> .			
IC <sub>50</sub> & Target	Human Endogenous Metabolite			
In Vitro	SAH (10 <sup>-7</sup> -10 <sup>-5</sup> M) activates norepinephrine (NE) and serotonin (5-HT) in vitro uptake in synaptosomal preparations from rat brain, but does not affect dopamine (DA) uptake <sup>[1]</sup> . SAH (0.1-10 μM) shows strong inhibitory effects on METTL3-14 activity with an IC <sub>50</sub> value of 0.9 μM in Kinetic parameter			

# Product Data Sheet

 $\mathbb{NH}_2$ 

HO O  $\mathrm{NH}_2$ 

о́н о́н

determination of the METTL3-14 complex<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo SAH (administered i.v., i.p. or p.o. in 1-10 mg/kg) is sleep-inductive and anticonvulsant with rabbit, rat and cat<sup>[1]</sup>. SAH (intraperitoneal injection; 7 mg/kg; 1 h prior to sacrifice) induces in vitro uptake increase for NE and 5-HT, significant only in brain stem and midbrain, but does not alter DA uptake<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **CUSTOMER VALIDATION**

- Apoptosis. 2022 Jun;27(5-6):426-440.
- Mol Med. 2023 Jul 3;29(1):86.
- Int J Mol Sci. 2024 Jan 5, 25(2), 733.
- Bone. 2022 Jan;154:116182.
- Oncol Lett. 2021 Oct;22(4):711.

See more customer validations on www.MedChemExpress.com

### REFERENCES

[1]. DE LA HABA G, et al. The enzymatic synthesis of S-adenosyl-L-homocysteine from adenosine and homocysteine. J Biol Chem. 1959 Mar;234(3):603-8.

[2]. Li F, et al. A Radioactivity-Based Assay for Screening Human m6A-RNA Methyltransferase, METTL3-METTL14 Complex, and Demethylase ALKBH5. Biomol Screen. 2016 Mar;21(3):290-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA